

EXTRAORDINARY GENERAL MEETING

TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED

(Formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited)

(Company Registration No.91120000103100784F)

(Incorporated in the People's Republic of China)

(the "**Company**")

NOTICE OF EXTRAORDINARY GENERAL MEETING

IMPORTANT NOTE FOR S-SHARE SHAREHOLDERS:

This Notice of Extraordinary General Meeting has been given in compliance with Article 69 of the Articles of Association of the Company and the listing rules of the Shanghai Stock Exchange which require the Company to issue a written notice 45 days in advance of a shareholders' meeting.

The Company will issue an updated Notice of Extraordinary General Meeting 14 days before the Extraordinary General Meeting in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, to provide the S-Share Shareholders with the details in relation to the arrangements for participation at the Extraordinary General Meeting by S-Share Shareholders in Singapore. S-Share Shareholders should check the SGXNET for the latest updates on the status of the Extraordinary General Meeting.

NOTICE IS HEREBY GIVEN that an extraordinary general meeting ("**EGM**" or "**Extraordinary General Meeting**") of the Company will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the People's Republic of China 300193 (concurrently, a video conferencing at RNN Conference Centre, 137 Cecil Street #12-02 Cecil Building, Singapore 069537 for holders of the S-Shares ("**S-Share Shareholders**") in Singapore) on Tuesday, 29 October 2024 at 2:00 p.m..

To consider and, if thought fit, approve the following resolutions, with or without modifications:

Resolution 1: To consider and approve the proposed capital injection into Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) by the Company through the transfer of the 100% equity interest in the registered capital of Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) to Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) and the proposed entry into a capital injection agreement in relation thereto as an interested person transaction;

Resolution 2: To consider and approve the resultant joint venture in Tianjin Pharmaceutical Group Taiping Medicine Co., Ltd. (津药太平医药有限公司) as an interested person transaction; and

Resolution 3: To consider and approve the proposed provision of a guarantee for an amount of up to RMB832,650,000 by the Company for Tianjin Zhongxin Medicine Co., Ltd. (天津中新医药有限公司) as an interested person transaction.

By Order of the Board

Jiao Yan
Secretary to the Board of Directors
11 September 2024

Notes:

1. The EGM will be held at the meeting room of Da Ren Tang Mansion, No. 17 Baidi Road, Nankai District, Tianjin, the People's Republic of China 300193 (concurrently, a video conferencing at RNN Conference Centre, 137 Cecil Street #12-02 Cecil Building, Singapore 069537 for S-Share Shareholders in Singapore) on Tuesday, 29 October 2024 at 2:00 p.m..

As mentioned above, the Company will issue an updated Notice of EGM 14 days before the EGM in compliance with the listing rules of the Singapore Exchange Securities Trading Limited, to provide S-Share Shareholders with the details in relation to the arrangements for participation at the EGM by S-Share Shareholders in Singapore. S-Share Shareholders should check the SGXNET for the latest updates on the status of the EGM.

2. A Shareholder (whether individual or corporate) entitled to attend and vote at the EGM is entitled to appoint one (1) or more persons (who need not also be a Shareholder) to act as his/ her/ its proxy(ies) to attend and vote on his /her/ its behalf at the EGM. Where a Shareholder appoints more than one (1) proxy, the appointment shall be deemed to be as an alternative unless he/ she/ it specifies the proportion of his/ her/ its shareholding (expressed as a percentage of the whole) to be represented by each proxy.

If the appointor is a corporation, the proxy must be executed under seal or the hand of its duly authorised officer or attorney.

3. Pursuant to the Articles of Association of the Company, a holder of tradable domestic A-Shares with limiting conditions for sale shall notify the Company in writing not less than 20 days prior to the EGM of his or her intention to attend the EGM. Accordingly, a holder of tradable domestic A-Shares with limiting conditions for sale who is planning to attend the EGM must give a written notice to the Company no later than 3 October 2024.
4. The EGM in Tianjin, the People's Republic of China is expected to last for half a day and all accommodation and other expenses incurred by a Shareholder or his/ her/ its proxy(ies) in connection with his/ her/ its attendance at the EGM shall be borne by that Shareholder.
5. **Personal data privacy:** By (1) submitting a proxy form appointing a proxy(ies) and/ or representative(s) to attend, speak and vote at the EGM and/ or any adjournment thereof, (2) submitting any question prior to the EGM, a Shareholder of the Company (a) consents to the collection, use and disclosure of the Shareholder's personal data by the Company (or its agents or service providers) for the purposes of (i) the processing and administration by the Company (or its agents or service providers) of proxies and representatives appointed for the EGM (including any adjournment thereof), (ii) the preparation and compilation of the attendance lists, minutes and other documents relating to the EGM (including any adjournment thereof), (iii) the addressing of substantial and relevant questions relating to the resolutions to be tabled for approval at the EGM from Shareholders received prior to and/ or at the EGM and if necessary, the following up with Shareholders in relation to such questions, and (iv) in order for the Company (or its agents or service providers) to comply with any applicable laws, listing rules, regulations and/ or guidelines (collectively, the "Purposes"), (b) warrants that where a Shareholder discloses the personal data of such Shareholder's proxy(ies) and/ or representative(s) to the Company (or its agents or service providers), such Shareholder has obtained the prior consent of such proxy(ies) and/ or representative(s) for the collection, use and disclosure by the Company (or its agents or service providers) of the personal data of such proxy(ies) and/ or representative(s) for the Purposes, and (c) agrees that the Shareholder will indemnify the Company in respect of any penalties, liabilities, claims, demands, losses and damages as a result of the Shareholder's breach of warranty.